---
schema_version: "secwatch.filing_event.v1"
accession: "0001708599-25-000002"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2025-01-06T23:59:59+00:00"
generated_at: "2026-05-28T10:58:58.972902+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# Serina Therapeutics files investor presentation with preliminary 2024 data; no specific figures disclosed

## Summary
- Exhibit 99.1 provides a presentation highlighting Serina's POZ Platform for drug delivery.
- Filing states preliminary unaudited financial info as of Dec 31, 2024, but these figures are not included in the filing text or exhibit excerpt.
- Presentation mentions RNA delivery and improved ADCs, but no revenue, cash, or other concrete financial metrics are given.
- The company is an emerging growth company; audit of full-year 2024 results is ongoing.

## SEC filing metadata
- accession: 0001708599-25-000002
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2025-01-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000002/0001708599-25-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000170859925000002/ser-20250106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001708599-25-000002
- JSON: https://secwatch.observer/filing/0001708599-25-000002.json
- Plain text: https://secwatch.observer/filing/0001708599-25-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.